Want to see DE:HPHA full AI Analyst Report?
Heidelberg Pharma AG (HPHA) Drug Pipeline
5 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Hdp-101 | Multiple Myeloma, Plasma Cell Disorder | phase1AndPhase2 | Recruiting | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Apr 23, 2021 | ― |
| Iodine (124I) Girentuximab | Renal Cell Carcinoma, Kidney Cancer | Phase III | Withdrawn | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT | Dec 19, 2012 | ― |
| 124-Iodine-Cg250 (124I-Cg250), Ct | Renal Cell Carcinoma, Kidney Cancer | Phase III | Completed | Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody | Jan 21, 2008 | ― |
| Girentuximab | Kidney Cancer | Phase III | Completed | Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | Jul 08, 2004 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Hdp-101 | phase1AndPhase2 | Multiple Myeloma, Plasma Cell Disorder | Recruiting | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Apr 23, 2021 | ― |
| Iodine (124I) Girentuximab | Phase III | Renal Cell Carcinoma, Kidney Cancer | Withdrawn | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT | Dec 19, 2012 | ― |
| 124-Iodine-Cg250 (124I-Cg250), Ct | Phase III | Renal Cell Carcinoma, Kidney Cancer | Completed | Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody | Jan 21, 2008 | ― |
| Girentuximab | Phase III | Kidney Cancer | Completed | Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | Jul 08, 2004 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Heidelberg Pharma AG (DE:HPHA) have in its pipeline
Heidelberg Pharma AG DE:HPHA is currently developing the following drugs: Hdp-101, Iodine (124I) Girentuximab, 124-Iodine-Cg250 (124I-Cg250), Ct, Girentuximab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
